Needham & Company Maintains Bullish Stance on Acadia (ACAD)

May 8, 2013 8:48 AM

Needham & Company reiterated its Buy rating and $16 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following Q1 results and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found